Date: 2016-01-19
Type of information: Nomination
Compound:
Company: AmpliPhi BioSciences (USA - VA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 19, 2016, AmpliPhi Biosciences announced that Steve R. Martin has been appointed as its new Chief Financial Officer. He will be based in AmpliPhi’s San Diego office. Mr. Martin brings over 30 years of progressive experience in senior financial roles including leadership positions in publicly-traded pharmaceutical companies. Mr. Martin served for three years as the CFO of Apricus Biosciences, a publicly-traded pharmaceuticals company. Prior to Apricus, he was CFO and interim CEO of BakBone Software, where he led the sale of the company to Quest Software. Previously, Mr. Martin was senior consultant to the CEO and Acting Chief Accounting Officer for Leap Communications, a $2 billion telecommunications company. Mr. Martin’s leadership experience includes serving as CFO of Stratagene Corporation, sold to Agilent Technologies in 2007 for $240 million and as Controller for Gen-Probe, acquired by Hologic. Mr. Martin began his career at Deloitte, where he spent 10 years in its San Diego office, rising to Senior Audit Manager. Mr. Martin has a B.S. in Accounting from San Diego State University and is the past President of the San Diego Chapter of Financial Executives International, a committee member of the Corporate Directors Forum and is a member of the San Diego Holiday Bowl Committee. AmpliPhi’s interim CFO, David E. Bosher, remains with AmpliPhi as a consultant.
Financial terms:
Latest news:
